Aurora Spine Corporation
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aurora Spine Corporation, through its operating subsidiary, Aurora Spine, Inc., stands as an innovator in developing and marketing advanced, minimally invasive surgical technologies for the spine and interventional pain management across Canada and internationally. The company delivers a diverse portfolio of interspinous process lumbar fusion systems, including its signature ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 devices, designed to address degenerative disc conditions. Their offerings also encompass Ti-Coated PEEK and titanium plasma spray coated interbody cages, which facilitate vertebral spacing and stability to promote bone fusion. Expanding its product range, Aurora Spine provides various interbody solutions such as the EOS, VOX, Echo, Echo SD, and EchoXL for lumbar spinal procedures, alongside the Discovery and the advanced DEXA-C system for cervical applications. The DEXA-C implant is a porous, 3D-printed intervertebral body fusion device, offering customizable lattice patterns to align with varying patient bone qualities. Further innovations include the SOLO, a 3D-printed anterior lumbar interbody fusion stand-alone device featuring an integrated plate and spacer for anatomical preservation and spinal column support, and the SiLO and SiLO-TFX, posterior fusion solutions specifically for the sacroiliac joint. Recently, Aurora Spine has introduced its Hydra A.E.R.O.™ facet fusion system and the DEXA-L anterior lumbar interbody fusion device, expanding its DEXA Technology™ platform which focuses on patient bone density matching. In a strategic move in October 2025, the company launched Aurora Biologics, a new division aimed at enhancing spinal fusion success with best-in-class biologic products. The company recorded an impressive $17.6 million in revenue for fiscal year 2024, representing a 21% increase over the previous year. Although Q3 2025 saw a slight revenue dip to $4.43 million amidst a product transition, Aurora Spine achieved positive EBITDAC for the second consecutive quarter. Established in 2013 and headquartered in Toronto, Canada, Aurora Spine continues to advance its mission of simplifying complex spinal challenges.
Company News
Aurora Spine Corporation Announces Second Quarter FY26 Financial Results
Aurora Spine Announces Settlement of Arbitration, New Patent License Agreement for SI Joint Product and Increase in Funding from Insider
Aurora Spine and CornerLoc Announce Strategic Commercial Alliance to Expand Minimally Invasive Spine and SI Joint Solutions Nationwide
Aurora Spine Grants Stock Options
Aurora Spine Corporation (ASG:CA) Q1 2026 Earnings Call Transcript
Aurora Spine Corporation Announces First Quarter FY26 Financial Results
Aurora Spine Corporation Schedules Release of First Quarter Fiscal 2026 Financial Results
Aurora Spine Corporation Schedules Release of First Quarter Fiscal 2026 Financial Results
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants
Aurora Spine Corporation (ASG:CA) Q4 2025 Earnings Call Transcript
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2025 Financial Results
Aurora Spine Corporation to Participate in the 38th Annual ROTH Conference
AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER
Aurora Spine Announces Issuance of Two U.S. Patents
Aurora Spine Corporation (ASG:CA) Q3 2025 Earnings Call Transcript
Aurora Spine Corporation Announces Record Third Quarter Financial Results
Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting
Aurora Spine Launches New Biologics Portfolio